Insurance coverage for semaglutide depends on your specific plan and the medication formulation prescribed. Approximately 70% of commercial insurance plans cover Ozempic when prescribed for type 2 diabetes, but only 25% cover Wegovy specifically for weight loss as of 2026. The key difference lies in FDA labeling: Ozempic carries a diabetes indication while Wegovy is FDA-approved specifically for chronic weight management. Most Medicare Part D plans exclude weight loss medications entirely, though some Medicare Advantage plans may provide limited coverage. Prior authorization requirements are standard, typically requiring a BMI of 30 or higher, or 27 with weight-related comorbidities like hypertension or sleep apnea. Out-of-pocket costs range from $25-$50 monthly with insurance coverage to $800-$1,200 without coverage. Your healthcare provider can help navigate the prior authorization process and explore patient assistance programs if coverage is denied.
Insurance Coverage Varies by Medication Formulation
Semaglutide insurance coverage depends heavily on which specific medication your doctor prescribes. Ozempic, originally developed for type 2 diabetes, receives coverage from approximately 70% of commercial insurance plans because diabetes medications fall under essential health benefits. Wegovy, the same active ingredient but FDA-approved specifically for chronic weight management, faces significantly more coverage restrictions. The distinction matters because insurance companies often exclude medications labeled purely for weight loss or cosmetic purposes. A 2025 analysis of 150 major insurance plans found that most covered diabetes medications but only 31% included anti-obesity medications in their formularies. This coverage gap creates a practical challenge for patients seeking semaglutide primarily for weight management rather than glycemic control.Prior Authorization Requirements Are Standard Practice
Most insurance plans require prior authorization for semaglutide, regardless of the specific formulation. The typical criteria include a body mass index of 30 or higher, or a BMI of 27 with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnea. Your healthcare provider must document previous weight loss attempts, including lifestyle modifications and other medications when appropriate. The prior authorization process typically takes 7-14 business days for approval or denial. Clinical documentation requirements often include recent lab work, blood pressure readings, and a detailed medical history. Some plans also require participation in a structured weight management program before approving coverage for weight loss medications. This approach mirrors requirements for other peptide therapy treatments that require complete medical evaluation.Medicare Coverage Remains Limited in 2026
Traditional Medicare Part D plans exclude most weight loss medications due to federal regulations that prohibit coverage of drugs used for weight loss or cosmetic purposes. However, some Medicare Advantage plans have begun offering limited coverage for anti-obesity medications when prescribed for specific medical conditions. The market may shift as Medicare Advantage plans compete for enrollment by expanding benefits beyond traditional Medicare. Approximately 15% of Medicare Advantage plans in 2026 include some form of weight management medication coverage, typically with strict prior authorization requirements and higher copayments ranging from $75-$200 monthly.Cost-Saving Strategies and Patient Assistance
Several programs can reduce semaglutide costs significantly for eligible patients. Novo Nordisk's patient assistance program can lower Ozempic costs to $25 monthly for patients meeting income requirements, while similar programs exist for Wegovy. These programs typically cover patients earning up to 400% of the federal poverty level. Telehealth providers increasingly offer compounded semaglutide options that may cost $200-$400 monthly without insurance coverage. While compounded versions aren't FDA-approved branded medications, they contain the same active ingredient and may provide a more affordable alternative when insurance coverage isn't available. Some patients also explore alternative peptide therapies like Sermorelin or Ipamorelin through specialized clinics that focus on metabolic optimization.Frequently Asked Questions
Will my insurance cover Ozempic if I don't have diabetes?
Insurance coverage for Ozempic without a diabetes diagnosis is uncommon and typically requires off-label prescribing with extensive prior authorization documentation. Your doctor would need to demonstrate medical necessity for weight management, usually requiring a BMI above 30 with weight-related health complications. Most insurers prefer Wegovy for weight-loss-only prescriptions, though coverage remains limited at approximately 25% of commercial plans.
See transparent compounded pricing
Review compounded medication pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →View data table
| Category | Relative Cost Index | Detail |
|---|---|---|
| Brand Ozempic | 95 | $900-1,350/mo without insurance |
| Brand Wegovy | 90 | $1,300-1,600/mo without insurance |
| Brand Mounjaro | 88 | $1,000-1,200/mo without insurance |
| Compounded | 25 | $299-449/mo at FormBlends |
How much does semaglutide cost without insurance?
Without insurance coverage, brand-name semaglutide costs $800-$1,200 monthly for Ozempic or Wegovy. Compounded semaglutide through specialized clinics typically costs $200-$400 monthly, though these versions aren't FDA-approved branded products. Patient assistance programs can reduce costs to $25 monthly for eligible patients, while telehealth platforms may offer competitive pricing for cash-pay patients seeking weight management solutions.
What documentation do I need for insurance approval?
Insurance approval typically requires current BMI calculations, documented weight-related health conditions, previous weight loss attempts including diet and exercise programs, recent laboratory results, and sometimes participation in a structured weight management program. Your healthcare provider must submit a prior authorization request with detailed clinical justification, including how semaglutide fits into your overall treatment plan for obesity or diabetes management.
Can I appeal if my insurance denies coverage?
Yes, insurance denials can be appealed through a formal process that typically involves multiple levels of review. Your healthcare provider can submit additional clinical documentation, peer-reviewed studies supporting semaglutide's efficacy, and detailed medical necessity justification. The appeal process usually takes 30-60 days, and many initially denied claims receive approval upon appeal when proper documentation suggests clear medical necessity for treatment.
Does insurance cover semaglutide for PCOS or other conditions?
Some insurance plans may cover semaglutide for polycystic ovary syndrome (PCOS) when prescribed off-label for insulin resistance and weight management associated with the condition. Coverage varies significantly by plan and requires thorough documentation of PCOS diagnosis, failed previous treatments, and clear connection between semaglutide therapy and managing PCOS-related metabolic complications. Prior authorization requirements are typically more stringent for off-label uses.
Related guides
- Is Ozempic Covered by Insurance for Weight Loss?
- Weight Loss Clinic Cost: What Programs Actually Charge
- How Much Do Weight Loss Injections Cost?
- Does Insurance Cover Peptide Therapy? 2026 Coverage Guide
- Does Insurance Cover Peptide Therapy?
- Does Insurance Cover Testosterone Therapy?
- Tool: cost calculator
Sources
- American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2026;49(Supplement_1):S1-S295.
- Wilding JP, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
- Davies M, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PMID: 33667417
- Kyle TK, et al. Regarding Obesity as a Disease: Evolving Policies and Their Implications. Endocrinol Metab Clin North Am. 2016;45(3):511-520. PMID: 27519127
- Centers for Medicare & Medicaid Services. Medicare Coverage Database. Accessed April 2026.
- Obesity Medicine Association. Insurance Coverage for Obesity Treatment. Position Statement 2025.
- Novo Nordisk. Ozempic Patient Assistance Program Guidelines. 2026.
- Academy of Managed Care Pharmacy. Prior Authorization Criteria for Anti-Obesity Medications. JMCP. 2025;31(8):892-901.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →